Table 2.

Median predicted probability of 5-year overall survival and observed 5-year overall survival rate in the study population.

		% 5 years OS
		Predicted	Observed	s. e.	Difference (95% CI)
All patients	2794	88.00	94.69	0.44	−6.69 (−7.55 to–5.83)
Type of anti-HER2 therapy
Lapatinib + trastuzumab	925	87.90	94.88	0.75	−6.98 (−8.45–5.51)
Trastuzumab alone	936	87.90	94.18	0.79	−6.28 (−7.83–4.73)
Trastuzumab followed by lapatinib	933	88.20	95.02	0.73	−6.82 (−8.25–5.39)
Type of chemotherapy
Non-anthracycline-based	322	88.15	96.22	1.12	−8.07 (−10.27–5.87)
Anthracycline-based	2472	87.95	94.51	0.47	−6.56 (−7.48–5.64)
Age at randomization
≤40	495	90.40	95.64	0.95	−5.24 (−7.10–3.38)
41–64	1989	88.20	94.91	0.51	−6.71 (−7.71–5.71)
≥65	310	82.05	91.78	1.61	−9.73 (−12.89–6.57)
Central HR status
Negative	1185	80.20	93.15	0.76	−12.95 (−14.44–11.46)
Positive	1609	93.10	95.82	0.52	−2.72 (−3.74–1.70)
Number of positive lymph nodes
0	567	91.80	97.93	0.62	−6.13 (−7.35–4.91)
1–3	945	87.40	96.40	0.63	−9.00 (−10.23–7.77)
≥4	709	71.80	87.61	1.27	−15.81 (−18.30–13.32)
Tumor size (mm)
≤20 mm	1248	91.25	97.43	0.46	−6.18 (−7.08–5.28)
21–50 mm	1356	86.00	93.33	0.70	−7.33 (−8.70–5.96)
>50 mm	190	71.05	86.37	2.59	−15.32 (−20.40–10.24)

OS overall survival, s.e. standard error, CI confidence interval, CT chemotherapy, HR hormone receptors.